Drugs / Radioactive iodine
Radioactive iodine
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04892303 | Mar 2021 → Dec 2027 expected | differentiated thyroid carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05299437 | May 2021 → Mar 2024 | differentiated thyroid carcinoma | Carlo Chiesa | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05142904 | Nov 2021 → Nov 2024 | hyperthyroidism, thyroid hormone metabolism, abnormal | Rijnstate Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT00196729 | Dec 2001 → Sep 2003 | thyroid tumor | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00115895 | Jan 2000 → Oct 2004 | thyroid tumor | University of Helsinki | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT04354324 | Apr 2020 → Jun 2024 | thyroid gland papillary carcinoma | Zhujiang Hospital | Unknown | No outcome recorded |
| — | NCT00430547 | Aug 2003 → Jan 2006 | disease of orbital part of eye adnexa | Barwon Health | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04447183 Background | Nov 2020 → Aug 2024 | differentiated thyroid carcinoma | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01843062 Background | Aug 2013 → May 2018 | differentiated thyroid carcinoma | AstraZeneca | Terminated | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-08-15 | Ipsen | Ipsen receives positive CHMP opinion for Cabometyx® in radioactive iodine-refractory differentiated thyroid cancer ipsen.com ↗ |
| 2022-05-03 | Ipsen | European Commission approves Cabometyx® as a second-line treatment for people living with radioactive iodine-refractory differentiated thyroid cancer ipsen.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Radioactive iodine | “radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral” NCT04447183 ↗ |
| Known as | 131-I | “Adult subjects (n = 160) diagnosed with papillary or follicular thyroid carcinoma were randomly allocated to receive either 1100 MBq (30 mCi) or 3700 MBq (100 mCi) activity of...” PMID 18382668 ↗ Apr 20085“A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization.” NCT01843062 ↗ “All patients received the same amount of radioactive iodine (100 mCi or 3.7 GBq of 131I).” NCT00196729 ↗ “124-I blood and lesion dosimetry will be used to optimize the 131-I therapeutic activity.” NCT05299437 ↗ “radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral” NCT04447183 ↗ “radioactive iodine (RAI, 131-I)” NCT04892303 ↗ |
| Known as | I131 | “Carbimazole, radio-active iodine (I131)” NCT00430547 ↗ |
| Known as | Radioiodine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04354324 ↗ |
| Known as | RAI | “radioactive iodine (RAI)” NCT04892303 ↗ |
| Modality | Other / unclassified | “Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq” NCT00115895 ↗ |
| Route | Oral | “Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq” NCT00115895 ↗ |